Alzheimer's Disease Therapeutics Program (U01)Funding Number: RFA-AG-13-014
Funding Type: RFA
Release Date: October 31, 2012
Expiration Date: January 15, 2013
Web Site: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-014.html
The goal of this Funding Opportunity Announcement (FOA) is to provide support for investigators to develop new drugs for the prevention or treatment of Alzheimers disease (AD). Specifically, this initiative is aimed at researchers who have promising small molecule compounds but lack outside drug development expertise and infrastructure support to advance these compounds to the clinic. This Alzheimers Disease Therapeutics Program adjunct to the NIH Blueprint Neurotherapeutics Program will allow investigators access to a virtual pharma network of contract research organizations, technical and regulatory experts and project managers, with extensive biopharma-industry experience. The long-term goal of the Alzheimers Disease Therapeutics Program is to advance projects from medicinal chemistry optimization through Phase l clinical trials and facilitate industry partnership for their further development.